Amlovas AT

Indication

Amlovas AT is indicated

Essential hypertension.

Angina pectoris & hypertension as co-existing diseases.

Post MI.

Refractory angina pectoris where nitrate therapy has failed.

Dosage & Administration

The therapy is initiated with a single dose of this combination. Depending upon the therapeutic response, titration of the dosage is recommended. In elderly patients, it is advisable to initiate the therapy with half (½) tablet of fixed dose combination of Amlodipine & Atenolol i.e. 2.5 mg of Amlodipine & 25 mg Atenolol.

Precautions

Bronchospasm: The combination should be used with caution in patients with airway obstruction. Renal impairment: The combination can be used in patients with renal impairment. However, caution may be necessary if the creatinine clearance is less than 30 ml/min because of possible reduction in the excretion of unchanged Atenolol. Hepatic impairment: Caution may be necessary in the use of the combination in patients with severe liver damage because of prolongation of the elimination half-life of Amlodipine. Drug withdrawal: Since coronary heart disease may exist without being recognized, patients should be warned against stopping the drug suddenly. Any discontinuation should be gradual and under observation. Use in pregnancy: The combination should be used during pregnancy only if the expected benefit outweighs the potential fetal risk. Use in lactation: The combination should not be used by nursing mothers. If its use is considered necessary, breast-feeding should be stopped.